期刊
JOURNAL OF INFECTIOUS DISEASES
卷 210, 期 10, 页码 1549-1554出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiu305
关键词
HIV; sevelamer; microbial translocation; LPS; sCD14; soluble tissue factor; LDL; oxLDL
资金
- National Institutes of Health [U01 AI-68636, AI-68634, 2UM1AI069452-08, AI069501, UM1-A1069424, UM1-AI069534-08, 2UM1AI069412-08]
- National Institutes of Health. [AI069471, 2UMIAI069511-08, UM1 AI069424, 5UO1 AI069502-07, A1-069513, 2UM1A I069432, UL1 TR001082, AI069477, UM1AI069495, UL1TR000124, 5-P30-AI-045008-15, UL1 RR024160, UM1-AI068636, P30-AI027757, AI-076174]
Abnormal levels of inflammation are associated with cardiovascular disease and mortality in human immunodeficiency virus (HIV)-infected patients. Microbial translocation, which may cause inflammation, is decreased by sevelamer in patients undergoing hemodialysis. In this single-arm study, we evaluated the effects of 8 weeks of sevelamer therapy on 36 HIV-infected subjects who were not receiving antiretroviral therapy. Sevelamer did not significantly change markers of microbial translocation, inflammation, or T-cell activation. During sevelamer treatment, however, levels of soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol decreased significantly, whereas D-dimer levels increased. Thus, in this study population, sevelamer did not reduce microbial translocation but may have yielded cardiovascular benefits.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据